PRISM BioLab, Enters Into a Joint Research and Licensing Agreement With Ono
PRISM BioLab will utilize PepMetics, innovative small molecules that mimic three-dimensional structures of alpha-helix and beta-turns of peptides for drug discovery against oncology target selected b
Taihei Electric, TOKYO BASE, etc.
<1887>Japan Land Development Co., Ltd. Xymax Group Stock Holding Ratio 5.97% → 6.29% Reporting Obligation Date 2024/04/01 <1904>Taisei Onjo Co., Ltd. (API, Inc.) Stock Ownership Ratio 9.67% → 8.64% Reporting Obligation Date 2024/03/27 <1968>Taihei Electric Co., Ltd. Nomura Securities Co., Ltd. Stock Ownership Ratio 10.98% → 9.8
Convertible Stock List [Parabolic Signal Convertible Stock List]
○List of trading stocks market code stock name closing price SAR Tokyo Stock Exchange Prime <2163> Altner 2413 2278<2325> NJS 3195 3055 <2389> digital HD 1188 1082 <3104> Fujibo HD 4465 4335 <3150> Grimes 2238 2106 <3950>
List of Unrivaled Stocks (Part 1) [Ichimoku Equilibrium Chart/Kumoku Stock List]
○Kumojo Stock List Market Code Stock Name Closing Price Advance Span A Advance Span B Tokyo Stock Exchange Prime <3445> RS Techno 3015 2824 2900 <7989> Tachikawa Bly 1476 1472.25 1446 ○Kumo Gobble Stock List Market Code Stock Name Closing Price Leading Span A Advance Span B TSE Fly
Sibylla Biotech Enters a Strategic Drug Discovery Collaboration With Ono Pharmaceutical in Central Nervous System Disorders
MILAN--(BUSINESS WIRE)--Sibylla Biotech announced today a drug discovery collaboration with Ono Pharmaceutical Co., Ltd. (TSE: 4528) that will access Sibylla's cutting-edge Pharmacological Protein Ina
Jefferies Adjusts Ono Pharmaceutical's Price Target to 2,400 Yen From 2,300 Yen, Keeps at Hold
Ono Pharmaceutical (TYO:4528) has an average rating of hold and price targets ranging from 1,800 yen to 5,170 yen, according to analysts polled by Capital IQ.
InveniAI Announces Collaboration With Ono Pharmaceutical for Target Discovery
Teams will work together by leveraging InveniAI's technology platform to identify, evaluate, and optimize novel targets across Ono's diseases of interestOno will access InveniAI's AI platform AlphaMeld and its suite
Shattuck Labs Collaborates With Ono Pharmaceutical to Develop Fusion Proteins
Shattuck Labs (STTK), a clinical-stage biotechnology company, has entered into a drug discovery collaboration with Japan's Ono Pharmaceutical to generate bifunctional fusion proteins for pathways invo
Numab Therapeutics and Ono Pharmaceutical Announce an Option and Collaboration Agreement to Develop Multi-specific Antibody NM49 for Treatment of Cancer
NM49 is a multi-specific antibody identified through Numab's proprietary discovery and engineering technology platform designed to activate tumor associated macrophage phagocytosis Numab to receive upfront payment and
Shattuck Labs Forms Drug Development Alliance With Ono Pharmaceutical
Express News | Shattuck Labs Announces Drug Discovery Collaboration With Ono Pharmaceutical, For Bifunctional Fusion Proteins Targeting Certain Autoimmune And Inflammatory Disease Pathways, Shattuck To Receive Upfront And Be Eligible For Milestone Payments Of Upto $227M
Shattuck Labs Enters Into Strategic Collaboration and License Agreement With Ono Pharmaceutical to Generate Bifunctional Fusion Proteins for the Treatment of Autoimmune and Inflammatory Diseases
AUSTIN, TX and DURHAM, NC, Feb. 13, 2024 (GLOBE NEWSWIRE) -- Shattuck Labs, Inc. (Shattuck) (NASDAQ:STTK), a clinical-stage biotechnology company pioneering the development of bifunctional fusion proteins as a new
Ono Pharmaceutical GAAP EPS of ¥229.06, Revenue of ¥389.91B
Ono Pharmaceutical 9-Mos Net Y110.54B Vs Net Y95.66B
Ono Pharmaceutical Co. Ltd. (4528.TO) Osaka Nine Months Ended December 31 GROUP 2023 2022 Revenue Y389.90 bln Y339.02 bln Operating Profit
Aufruf Zur Einreichung Von Bewerbungen Von Forschern Für Ein Gemeinsames Forschungsprojekt Zwischen Ono Pharmaceutical Und BioMed X
- Forschungsthema: Neue Strategien zum Einsatz von Neurophilen bei soliden Tumoren - OSAKA, Japan, 9. Januar 2024 /PRNewswire/ -- Ono Pharmaceutical Co., Ltd. (Osaka, Japan) teilte mit, dass es eine
Call for Application to Researchers for Joint Research Project Between Ono Pharmaceutical and BioMed X
Ono Pharmaceutical Co., Ltd. (Osaka, Japan) informed that it has started a new collaboration with BioMed X (Heidelberg, Germany) on cancer...
BioMed X Institute and Ono Pharmaceutical Launch New Collaboration in Cancer Research
German research institute BioMed X and Ono Pharmaceutical, a Japanese pharmaceutical company, started a new joint research project on cancer immunotherapies.HEIDELBERG, GERMANY / ACCESSWIRE / December
Ono Pharmaceutical 1H Net Y74.49B Vs Net Y62.34B
Ono Pharmaceutical Co. Ltd. (4528.TO) Osaka 1st Half Ended September 30 GROUP 2023 2022 Revenue Y258.71 bln Y216.70 bln Operating Profit Y
Turbine Establishes Research Collaboration With Ono Pharmaceutical to Identify and Validate Novel Oncology Targets
— Leveraging Turbine's cell simulation technology to identify novel targets in one of Ono's priority cancer domains — Turbine, a computational biology company that deploys empirically validated in silico cell
Ono Pharmaceutical Co. (OPHLF) Upgraded to Buy: Here's Why
No Data